Suche   Â
DGAP-News: Exiqon introduces serum/plasma and cancer microRNA qPCR Arrays
ID: 471235
(firmenpresse) - Exiqon A/S
31.08.2011 14:21
---------------------------------------------------------------------------
Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value gene expression
analysis products, today launched two Focus microRNA PCR Panels for sensitive
and specific quantification of microRNAs in serum/plasma and in cancer samples.
The new Focus qPCR Panels offer researchers a head start along with a potential
for cost and time reduction in their studies. This is made possible because
Exiqon has conducted extensive screenings to identify the most important
microRNAs for profiling of serum/plasma and cancer samples. The new Focus
Panels therefor include only the relevant microRNAs for the specific field of
study.
Focus PCR Panels are available in both 96 and 384 well array formats based on
Exiqon's proprietary miRCURY LNA(tm) Universal RT microRNA PCR system that allows
for reliable microRNA profiling with only 1 pg of total RNA without any need
for pre-amplification and secures a minimum of bias in the generation of cDNA
because of the universal RT step.
The Focus Panels for serum/plasmais the result of a genome wide qPCR analysis
of more than 2,000 healthy individuals and patients with numerous different
diseases. A total of 175 microRNAs with particular relevance for serum/plasma
analysis has been identified by Exiqon for the Focus Panels for serum/plasma.
The Focus Panels for cancer is based on a genome wide qPCR analysis of more
than 5.000 cancer biopsies from more than 27 different types of cancers. This
has resulted in the identification of 88 microRNAs relevant for any cancer
research program.
More Focus Panels are planned by Exiqon.
In a comment, Senior Vice President Sales&Marketing, Dr. Henrik M.
Pfundheller said:
'We are excited about the launch of these first two Focus Panels in a series to
come. The launch comes just weeks after a recent publication by an independent
research group has documented the benefits of Exiqon's qPCR system compared to
competing products', and he added: 'Exiqon's Focus Panels contain the most
validated content available on the market today and allows researchers to take
advantage of Exiqon's pioneer work, knowledge and expertise in the field of
microRNA expression profiling'. Our Focus Panels provide researchers with a
head start and the ability to focus their research on that which is relevant to
them'.
Customers interested in microRNA profiling of cancer samples will benefit from
the new Focus Panel for cancer.
The Focus Panels for cancer contain qPCR assays for 88 microRNAs. Thousands of
samples covering over 27 different types of cancers have been studied by
genome-wide screening. Based on these results Exiqon has identified a set of
cancer relevant microRNAs in terms of microRNAs acting as important
oncomiR/tumor suppressor as well as microRNAs general to many types of cancers.
Also microRNAs identified as specific for particular types of cancer (cancer
classifiers) are included. The panel will help researchers to quickly and
accurately analyze cancer samples and help identify microRNA signatures and/or
significant microRNAs which may be possible disease biomarkers, which can be
used for diagnosis as well as to monitor the effect of therapy on cancer
prognosis and progression.
Customers interested in microRNA profiling of serum/plasma samples will benefit
from the new Focus Panel for serum/plasma.
The Focus Panels for serum/plasma contains qPCR assays for 175 microRNAs. All
175 microRNAs have been selected specifically for serum and plasma samples
based on our vast number of in-house analyses of microRNA expression in
serum/plasma samples. More than one (1) million data points from serum/plasma
samples that have been collected from normal as well as diseased individuals
have been used in the selection of relevant serum/plasma microRNAs for this
Focus Panel. This means microRNA expression data from different diseases stages
from various types of cancer, neurological disorders, inflammation etc.
Benefits of the miRCURY LNA(tm) Universal RT microRNA PCR system
An independent scientific benchmark study has recently demonstrated the
superior sensitivity and linearity of the miRCURY LNA(tm) Universal RT microRNA
PCR system. The benchmark study was performed by a research group at Aarhus
University Hospital, Skejby, Denmark, and was published on 26 August 2011in the
leading peer-reviewed scientific journal BMC Genomics. The study highlighted in
particular the superior linearity and sensitivity of the miRCURY LNA(tm) Universal
RT microRNA PCR platform within clinically important plasma and serum samples
which contain low amounts of microRNA.
The study can be accessed at the BMC Genomics website:
http://www.biomedcentral.com/1471-2164/12
Exiqon's product line for microRNA qPCR also includes ready-to-use panels for
genome-wide screening of human, mouse and rat microRNAs, custom Pick&Mix panels
as well as RT and Master Mix kits and unique qPCR data analysis software.
More information about the miRCURY LNA(tm) microRNA qPCR products is available at
Exiqon's website: http://www.exiqon.com/qPCR.
Additional information
Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Henrik M. Pfundheller, SVP Sales&Marketing, tel. +45 4565 0420 (cell: +45
4090 2106)
See the full release in the attached PDF or at www.exiqon.com/investor/portal
Click on, or paste the following link into your web browser, to view the associated documents
https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=360837
News Source: NASDAQ OMX
31.08.2011 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Exiqon A/S
Denmark
Phone:
Fax:
E-mail:
Internet:
ISIN: DK0060077758
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
  
  
  
Datum: 31.08.2011 - 14:21 Uhr
Sprache: Deutsch
News-ID 471235
Anzahl Zeichen: 7227
Kontakt-Informationen:
Kategorie:
Wirtschaft (allg.)
Diese Pressemitteilung wurde bisher 0 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Exiqon introduces serum/plasma and cancer microRNA qPCR Arrays"
steht unter der journalistisch-redaktionellen Verantwortung von
Exiqon A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).